PRVL - Prevail Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.09
-0.41 (-2.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close18.50
Open18.49
Bid16.10 x 800
Ask18.09 x 800
Day's range17.60 - 18.60
52-week range7.41 - 19.24
Volume130,378
Avg. volume110,325
Market cap616.905M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.65
Earnings date11-Nov-2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.33
  • GlobeNewswire

    Prevail Therapeutics Provides PR001 Program Update

    Prevail has granted a compassionate use request for the administration of PR001 to a single patient with Type 2 Gaucher disease via a compassionate use pathway, following approval by an international regulatory authority, and the patient was recently dosed. Type 2 Gaucher disease is the more severe form of nGD, which presents in infancy and involves rapidly progressing neurodegeneration leading to death in infancy or early childhood.

  • GlobeNewswire

    Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

    As previously reported, Prevail’s IND for PR001 for the treatment of nGD had been put on clinical hold by the FDA, and this clinical hold has now been removed. The Company’s planned Phase 1/2 clinical trial for nGD patients will commence at a dose higher than originally proposed.

  • GlobeNewswire

    Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation

    Prevail Therapeutics Inc. (PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation (ODD) for the company’s gene therapy candidate, PR006, for the treatment of patients with frontotemporal dementia (FTD) with a GRN mutation (FTD-GRN). PR006 is designed to increase progranulin levels in FTD-GRN patients by delivering a healthy GRN gene using an AAV9 vector.

  • GlobeNewswire

    Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors

    Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of Morgan Sheng, Ph.D., to its Board of Directors. “Morgan is an esteemed leader who brings a wealth of expertise in neuroscience and specifically drug development in neurodegenerative diseases,” said Francois Nader, M.D., Non-Executive Chairman of Prevail’s Board of Directors. Previously, he was Vice President of Neuroscience at Genentech, where he was head of neuroscience research and drug discovery.

  • GlobeNewswire

    Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for.

  • GlobeNewswire

    Prevail Therapeutics to Participate in Upcoming November Conferences

    NEW YORK, Nov. 06, 2019 -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based.

  • GlobeNewswire

    Prevail Therapeutics to Present at Upcoming October Conferences

    NEW YORK, Oct. 01, 2019 -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based.

  • GlobeNewswire

    Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

    Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that it will be added to the Russell 2000 and Russell 3000 and Microcap Indexes, effective after the close of the U.S. markets on Friday, September 20, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and represents approximately 10 percent of the total market capitalization of that index.

  • GlobeNewswire

    Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

    Prevail Therapeutics Inc. (NASDAQ: PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders, today provided an update on the Company’s clinical development of PR001, a potentially disease-modifying, single-dose gene therapy in development for Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail has an open Investigational New Drug Application (IND) for PR001 for the treatment of PD-GBA, the first indication the Company is pursuing.

  • GlobeNewswire

    Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference

    NEW YORK, Sept. 04, 2019 -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based.

  • GlobeNewswire

    Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

    IND Active for Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations Successful $125.0 Million Initial Public Offering Completed to Support.

  • GlobeNewswire

    Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

    Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that Asa Abeliovich, M.D., Ph.D., Founder and CEO, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 10:20 a.m. ET in New York City. Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.

  • Business Wire

    Prevail Therapeutics Announces Pricing of Initial Public Offering

    Prevail Therapeutics Inc. , a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.